Drug discovery in the ubiquitin regulatory pathway

Drug Discovery Today

Volumn 8, Issue 16, 2003, Pages 746-754

  Wong, Brian R ^a   Parlati, Francesco ^a   Qu, Kunbin ^a   Demo, Susan ^a   Pray, Todd ^a   Huang, Jianing ^a   Payan, Donald G ^a   Bennett, Mark K ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Cancer biology; Drug Discovery; Drug discovery; Genetics; HECT; Inflammation; Ligase; Molecular Medicine; Oncology; Pharmaceutical Science; RING; Small molecule; Structural Biology; Ubiquitin protease; Ubiqutin; Ubl; Virology

Indexed keywords

BORTEZOMIB; CARRIER PROTEIN; ISOPROTEIN; PROTEASOME INHIBITOR; PROTEINASE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; BIODIVERSITY; CARCINOMA; CENTRAL NERVOUS SYSTEM DISEASE; CONJUGATION; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; INFLAMMATION; METABOLISM; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; MUSCLE ATROPHY; NONHUMAN; ONCOLOGY; PARKINSON DISEASE; PATHOGENESIS; PHARMACOPHORE; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VIRUS INFECTION;

HUMANS; UBIQUITINS;

EID: 0042934147     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02780-6     Document Type: Review

References (81)

1. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533.
2. Walden H., et al. Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature. 422:2003;330-334.
3. Moraes T.F., et al. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat. Struct. Biol. 8:2001;669-673.
4. VanDemark A.P., et al. Molecular insights into polyubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell. 105:2001;711-720.
5. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2:2001;169-178.
6. Lin H., et al. Divergent N-terminal sequences target an inducible testis deubiquitinating enzyme to distinct subcellular structures. Mol. Cell. Biol. 20:2000;6568-6578.
7. Cope G.A., et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 298:2002;608-611.
8. Deng L., et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:2000;351-361.
9. Hofmann R.M., Pickart C.M. Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 96:1999;645-653.
10. Spence J., et al. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15:1995;1265-1273.
11. Katzmann D.J., et al. Receptor downregulation and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3:2002;893-905.
12. Ma M.H., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9:2003;1136-1144.
13. Peters J.M. SCF and APC: the Yin and Yang of cell cycle regulated proteolysis. Curr. Opin. Cell Biol. 10:1998;759-768.
14. Peters J.M. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell. 9:2002;931-943.
15. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
16. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:1998;129-139.
17. Gstaiger M., et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5043-5048.
18. Signoretti S., et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110:2002;633-641.
19. Masuda T.A., et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62:2002;3819-3825.
20. Wang C., et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 412:2001;346-351.
21. Malakhov, M.P. et al. High-throughput immunoblotting: ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem. (in press).
22. Malakhova O.A., et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 17:2003;455-460.
23. Malakhov M.P., et al. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 277:2002;9976-9981.
24. Malakhova O., et al. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J. Biol. Chem. 277:2002;14703-14711.
25. Gomes M.D., et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14440-14445.
26. Bodine S.C., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:2001;1704-1708.
27. Hampton R.Y., et al. Role of 26S proteasome and HRD genes in the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein. Mol. Biol. Cell. 7:1996;2029-2044.
28. Bays N.W., et al. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat. Cell Biol. 3:2001;24-29.
29. Gardner R.G., Hampton R.Y. A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes. J. Biol. Chem. 274:1999;31671-31678.
30. Lomaga M.A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13:1999;1015-1024.
31. Coscoy L., Ganem D. PHD domains and E3 ubiquitin ligases: viruses make the connection. Trends Cell Biol. 13:2003;7-12.
32. Garrus J.E., et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell. 107:2001;55-65.
33. Pornillos O., et al. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat. Struct. Biol. 9:2002;812-817.
34. Dawson T.M., Dawson V.L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111:2003;145-151.
35. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
36. Shimura H., et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269.
37. Yang Y., et al. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by pael-R in Drosophila. Neuron. 37:2003;911-924.
38. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
39. Maraganore D.M., et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860.
40. Liu Y., et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:2002;209-218.
41. Williams D.H., Mitchell T. Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Curr. Opin. Pharmacol. 2:2002;567-573.
42. Wilkinson K.D., et al. A specific inhibitor of the ubiquitin activating enzyme: synthesis and characterization of adenosyl-phospho-ubiquitinol, a nonhydrolyzable ubiquitin adenylate analogue. Biochemistry. 29:1990;7373-7380.
43. Sekizawa R., et al. Panepophenanthrin, from a mushroom strain, a novel inhibitor of the ubiquitin-activating enzyme. J. Nat. Prod. 65:2002;1491-1493.
44. Worthylake D.K., et al. Crystal structure of the Saccharomyces cerevisiae ubiquitin-conjugating enzyme Rad6 at 2.6 Å resolution. J. Biol. Chem. 273:1998;6271-6276.
45. Huang L., et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science. 286:1999;1321-1326.
46. Zheng N., et al. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 102:2000;533-539.
47. Hamilton K.S., et al. Structure of a conjugating enzyme-ubiquitin thiolester intermediate reveals a novel role for the ubiquitin tail. Structure (Camb). 9:2001;897-904.
48. Bernier-Villamor V., et al. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell. 108:2002;345-356.
49. Verdecia M.A., et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol. Cell. 11:2003;249-259.
50. Zheng N., et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:2002;703-709.
51. Schindler T., et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
52. Du F., et al. Pairs of dipeptides synergistically activate the binding of substrate by ubiquitin ligase through dissociation of its autoinhibitory domain. Proc. Natl. Acad. Sci. U. S. A. 99:2002;14110-14115.
53. Majeux N., et al. Efficient electrostatic solvation model for protein-fragment docking. Proteins. 42:2001;256-268.
54. Duncan S.J., et al. Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123:2001;554-560.
55. Stoll R., et al. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry. 40:2001;336-344.
56. Zhao J., et al. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183:2002;69-77.
57. Berleth E.S., et al. Inhibition of ubiquitin-protein ligase (E3) by mono- and bifunctional phenylarsenoxides. Evidence for essential vicinal thiols and a proximal nucleophile. J. Biol. Chem. 267:1992;16403-16411.
58. Swinney D.C., et al. A small molecule ubiquitination inhibitor blocks NF-κB-dependent cytokine expression in cells and rats. J. Biol. Chem. 277:2002;23573-23581.
59. Lai Z., et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;14734-14739.
60. Kussie P.H., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1996;948-953.
61. Johnston S.C., et al. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 18:1999;3877-3887.
62. Mossessova E., Lima C.D. Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell. 5:2000;865-876.
63. Hu M., et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 111:2002;1041-1054.
64. Leung-Tong R., et al. Thio-dependent enzymes and their inhibitors: review. Curr. Med. Chem. 9:2002;979-1002.
65. Borodovsky A., et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9:2002;1149-1159.
66. Mullally J.E., et al. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276:2001;30366-30373.
67. Mullally J.E., Fitzpatrick F.A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol. Pharmacol. 62:2002;351-358.
68. Li Y., et al. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. U. S. A. 100:2003;259-264.
69. Podust V.N., et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4579-4584.
70. Leng R.P., et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 112:2003;779-791.
71. Zhang Y., et al. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;974-979.
72. Kang D., et al. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J. Cell Biol. 156:2002;249-259.
73. Urano T., et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 417:2002;871-875.
74. Cai S.Y., et al. A mutant deubiquitinating enzyme (Ubp-M) associates with mitotic chromosomes and blocks cell division. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2828-2833.
75. Yang Y.L., Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 10:2000;169-177.
76. Wilkinson C.R. New tricks for ubiquitin and friends. Trends Cell Biol. 12:2002;545-546.
77. Baek K.H. Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines. Am. J. Hematol. 71:2002;340-345.
78. Wong B.R., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4:1999;1041-1049.
79. Naito A., et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 4:1999;353-362.
80. Perez O.D., Nolan G.P. Resistance is futile: assimilation of cellular machinery by HIV-1. Immunity. 15:2001;687-690.
81. Chen Y., et al. The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons. J. Biol. Chem. 275:2000;8929-8935.